Repare Therapeutics Inc. (RPTX)
- Previous Close
3.1500 - Open
3.1800 - Bid 3.1100 x 100
- Ask 3.1400 x 100
- Day's Range
3.1300 - 3.2280 - 52 Week Range
2.9800 - 13.8500 - Volume
43,046 - Avg. Volume
132,080 - Market Cap (intraday)
132.03M - Beta (5Y Monthly) 0.56
- PE Ratio (TTM)
-- - EPS (TTM)
-2.2300 - Earnings Date Feb 26, 2024 - Mar 1, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
15.33
Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.
www.reparerx.comRecent News: RPTX
Performance Overview: RPTX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RPTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RPTX
Valuation Measures
Market Cap
132.87M
Enterprise Value
-87.34M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.59
Price/Book (mrq)
0.63
Enterprise Value/Revenue
-1.71
Enterprise Value/EBITDA
0.76
Financial Highlights
Profitability and Income Statement
Profit Margin
-183.43%
Return on Assets (ttm)
-23.51%
Return on Equity (ttm)
-38.16%
Revenue (ttm)
51.13M
Net Income Avi to Common (ttm)
-93.8M
Diluted EPS (ttm)
-2.2300
Balance Sheet and Cash Flow
Total Cash (mrq)
223.63M
Total Debt/Equity (mrq)
1.61%
Levered Free Cash Flow (ttm)
-97.36M
Research Analysis: RPTX
Company Insights: RPTX
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: RPTX
Daily – Vickers Top Buyers & Sellers for 06/16/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 06/07/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 01/25/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.